Stocks · Health care · Biological Products, (No Diagnostic Substances)

Allogene Therapeutics, Inc.

ALLO Clue Score24

United States Fiscal year ends December CIK 0001737287 Results filed 5 Nov 2026

Add to watchlist

By person

11 insiders · 15 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

David D Chang

President and CEO

—

$289.46K (2)

−$289.46K

5,150,599

1.49%

$6.90M

+6.5%

Zachary Roberts

President and CEO

—

$104.17K (2)

−$104.17K

581,166

0.1682%

$778.76K

+12.8%

Earl Martin Douglas

SVP, General Counsel

—

$103.26K (2)

−$103.26K

488,267

0.1413%

$654.28K

+21.4%

Geoffrey M. Parker

Chief Financial Officer

—

$90.94K (2)

−$90.94K

1,045,877

0.3027%

$1.40M

+7.4%

Benjamin Machinas Beneski

SVP, Chief Technical Officer

—

$51.67K (5)

−$51.67K

195,338

0.0565%

$261.75K

+1.6%

Annie Yoshiyama

SVP, Finance

—

$29.31K (2)

−$29.31K

124,517

0.0360%

$166.85K

+11.5%

Arie Belldegrun

Director

—

2,236,816

0.6474%

$3.00M

+19.8%

Joshua A Kazam

Director

—

398,463

0.1153%

$533.94K

+31.5%

Franz B Humer

Director

—

307,507

0.0890%

$412.06K

−2.9%

Timothy L. Moore

Chief Technical Officer

—

250,713

0.0726%

$335.96K

−5.6%

Deborah M. Messemer

Director

—

107,431

0.0311%

$143.96K

−35.6%

Allogene Therapeutics, Inc.

What the insiders did Net selling

By person